A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the U.S.

Q4 2024 Management View CEO Punit Dhillon highlighted significant progress with the clinical development of nimacimab, including the completion of patient enrollment for the CBeyond Phase IIa trial ...

MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25Progression of preclinical next-generation ...

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States and a top ...

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these industries, ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Despite advances in anticoagulant therapies, bleeding remains a critical concern.Traditionally, the definition of major ...

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide ...

Charles Schwab Investment Management Inc. grew its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 3.4% ...